Our recent investigations showed in vitro that a new pharmaceutical device containing mesoglycan, the Prisma® Skin, enhances re-epithelialization and granulation processes. This device induces a strong cytoskeletal re-organization to enhance cell migration/invasion, showing the increase of Fibroblast Activated Protein α and a remarkable change in fibroblast shape and orientation. In this case series we obtained preliminary evidences about the beneficial effects of Prisma® Skin device on patients. This pilot study was performed on seven permanently bedded patients affected by pressure ulcers and focusing on fibroblast activity, to confirm our in vitro results. The haematoxylin-eosin and immunohistochemical staining of patients’ biopsies have been used to assess the relevant cell structures of tissue samples. We started the evaluation at a T0 point proved the lack of cell structure in the analyzed tissues with a tendency to wound bed sclerosis, and reduced inflammatory activity. Then, after 14 days of treatment with Prisma® Skin, we founded a relevant formation of granulation tissue. The strong increase of vimentin expression confirmed not the wound closure than a strong fibroblasts recruitment on patients’ skin biopsies. Our clinical preliminary study shows, for the first time, the positive effects on tissue repair of Prisma® Skin on patients’ pressure ulcers.
A new pharmaceutical device containing mesoglycan modulates fibroblasts function in vivo
Belvedere R.Writing – Review & Editing
;Bizzarro V.Writing – Original Draft Preparation
;Pessolano E.Membro del Collaboration Group
;Parente L.Membro del Collaboration Group
;Petrella A.
Supervision
2020-01-01
Abstract
Our recent investigations showed in vitro that a new pharmaceutical device containing mesoglycan, the Prisma® Skin, enhances re-epithelialization and granulation processes. This device induces a strong cytoskeletal re-organization to enhance cell migration/invasion, showing the increase of Fibroblast Activated Protein α and a remarkable change in fibroblast shape and orientation. In this case series we obtained preliminary evidences about the beneficial effects of Prisma® Skin device on patients. This pilot study was performed on seven permanently bedded patients affected by pressure ulcers and focusing on fibroblast activity, to confirm our in vitro results. The haematoxylin-eosin and immunohistochemical staining of patients’ biopsies have been used to assess the relevant cell structures of tissue samples. We started the evaluation at a T0 point proved the lack of cell structure in the analyzed tissues with a tendency to wound bed sclerosis, and reduced inflammatory activity. Then, after 14 days of treatment with Prisma® Skin, we founded a relevant formation of granulation tissue. The strong increase of vimentin expression confirmed not the wound closure than a strong fibroblasts recruitment on patients’ skin biopsies. Our clinical preliminary study shows, for the first time, the positive effects on tissue repair of Prisma® Skin on patients’ pressure ulcers.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
